ES2936811T3 - Conjugado para inducir anticuerpos dirigidos a polisacáridos de la pared celular fúngica - Google Patents

Conjugado para inducir anticuerpos dirigidos a polisacáridos de la pared celular fúngica Download PDF

Info

Publication number
ES2936811T3
ES2936811T3 ES14774732T ES14774732T ES2936811T3 ES 2936811 T3 ES2936811 T3 ES 2936811T3 ES 14774732 T ES14774732 T ES 14774732T ES 14774732 T ES14774732 T ES 14774732T ES 2936811 T3 ES2936811 T3 ES 2936811T3
Authority
ES
Spain
Prior art keywords
chitin
compound
vaccine
antibodies
fungal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14774732T
Other languages
English (en)
Spanish (es)
Inventor
Francis Michon
Frank Comer
Kuishu Ren
Samuel J Wohlstadter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Vaccines LLC
Original Assignee
Wellstat Vaccines LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Vaccines LLC filed Critical Wellstat Vaccines LLC
Application granted granted Critical
Publication of ES2936811T3 publication Critical patent/ES2936811T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
ES14774732T 2013-03-12 2014-03-06 Conjugado para inducir anticuerpos dirigidos a polisacáridos de la pared celular fúngica Active ES2936811T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361777631P 2013-03-12 2013-03-12
PCT/US2014/021128 WO2014158963A1 (en) 2013-03-12 2014-03-06 Antibodies targeted to fungal cell wall polysaccharides

Publications (1)

Publication Number Publication Date
ES2936811T3 true ES2936811T3 (es) 2023-03-22

Family

ID=51625093

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14774732T Active ES2936811T3 (es) 2013-03-12 2014-03-06 Conjugado para inducir anticuerpos dirigidos a polisacáridos de la pared celular fúngica

Country Status (10)

Country Link
US (6) US20160017062A1 (https=)
EP (1) EP2968427B1 (https=)
JP (2) JP6434958B2 (https=)
CN (1) CN105188725B (https=)
AU (1) AU2014241492A1 (https=)
DK (1) DK2968427T3 (https=)
ES (1) ES2936811T3 (https=)
FI (1) FI2968427T3 (https=)
PL (1) PL2968427T3 (https=)
WO (1) WO2014158963A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014158963A1 (en) 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
CN111679069A (zh) * 2019-12-31 2020-09-18 安徽中医药大学 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法
CN111707815A (zh) * 2019-12-31 2020-09-25 安徽中医药大学 一种通过白色念珠菌细胞壁重构来评价中药单体抗真菌作用的方法
CN113274489B (zh) * 2021-04-30 2023-08-29 山东省药学科学院 一种预防真菌感染的几丁质寡糖疫苗及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62138496A (ja) 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
JP2871822B2 (ja) * 1989-08-29 1999-03-17 玉造株式会社 末端に２，５―アンヒドロマンニトール基または２，５―アンヒドロマンノース基を有するキチン・キトサンオリゴマーおよびその製造方法
JP2868635B2 (ja) * 1991-02-25 1999-03-10 玉造株式会社 キチン・キトサンオリゴマーの精製方法
JP2786389B2 (ja) * 1993-05-18 1998-08-13 玉造株式会社 腫瘍免疫治療剤
US5705634A (en) 1995-03-02 1998-01-06 Perimmune Holdings, Inc. High yield preparation of dimeric to decameric chitin oligomers
US6284884B1 (en) * 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
DK1448607T3 (da) * 2001-11-15 2011-04-26 Piramal Healthcare Canada Ltd Sammensætning og fremgangsmåde til homogen modificering eller krydsbinding af chitosan under neutrale betingelser
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
EP1863536A4 (en) * 2005-03-14 2011-07-20 Univ Alberta VACCINE BASED ON SYNTHETIC OLIGOSACCHARIDES AGAINST CANDIDA ALBICANS
AU2006257177A1 (en) 2005-06-14 2006-12-21 Genis Ehf. Compositions of partially deacetylated chitin derivatives
KR100793756B1 (ko) * 2006-08-07 2008-01-10 엘지전자 주식회사 녹화 목록 표시 방법 및 그 장치
US20080311595A1 (en) 2007-06-18 2008-12-18 Inger Mattsby-Baltzer Rapid fungal detection assay and product
GB2460965B (en) * 2008-03-13 2010-05-19 Academia Sinica Fibrillar albumin and uses thereof
EP2123261A1 (en) 2008-05-20 2009-11-25 Stallergenes S.A. Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
US20110274713A1 (en) * 2008-08-05 2011-11-10 The University Of Queensland Antigen-presenting scaffolds
BRPI0918806B1 (pt) 2008-09-05 2019-02-05 Ceva Sante Animale Sa Composição de vacina compreendendo quitosana e antígeno do vírus de doença de newcastle (nvd) adaptada à administração ocular em ave, uso de quitosana e de nvd paraaumentar resposta imune em ave, bem como kit de vacinação de aves
KR101664510B1 (ko) 2008-10-23 2016-10-10 더루우브리졸코오포레이션 금속 카르복실레이트를 함유하는 윤활 조성물
JP5617127B2 (ja) * 2009-05-08 2014-11-05 大石　哲也 新規グアナミン化合物、その誘導体及びそれらの製造方法
JP5781542B2 (ja) * 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
JP2012241084A (ja) * 2011-05-18 2012-12-10 Nippon Terupen Kagaku Kk バインダー樹脂用溶剤
WO2014158963A1 (en) * 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides

Also Published As

Publication number Publication date
CN105188725B (zh) 2020-08-21
DK2968427T3 (da) 2023-01-30
US10752704B2 (en) 2020-08-25
US20190169315A1 (en) 2019-06-06
AU2014241492A1 (en) 2015-09-17
US10988552B2 (en) 2021-04-27
US10519253B2 (en) 2019-12-31
JP2016513747A (ja) 2016-05-16
US20200339707A1 (en) 2020-10-29
HK1220360A1 (en) 2017-05-05
US20200062866A1 (en) 2020-02-27
US20160017062A1 (en) 2016-01-21
US20180251573A1 (en) 2018-09-06
JP2018172696A (ja) 2018-11-08
FI2968427T3 (fi) 2023-03-01
US20210301037A1 (en) 2021-09-30
WO2014158963A1 (en) 2014-10-02
JP6434958B2 (ja) 2018-12-05
EP2968427A4 (en) 2016-08-31
PL2968427T3 (pl) 2023-02-27
EP2968427B1 (en) 2022-10-26
CN105188725A (zh) 2015-12-23
EP2968427A1 (en) 2016-01-20
US10259888B2 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
US10988552B2 (en) Antibodies targeted to fungal cell wall polysaccharides
CN105085349B (zh) 与合成的β‑1,6 葡糖胺寡糖相关的方法和组合物
CN109862908A (zh) 多价肺炎球菌多糖-蛋白质缀合物组合物
ES2826000T3 (es) Composiciones de polisacárido y métodos de uso
CN109890415A (zh) 多价肺炎球菌多糖-蛋白质缀合物组合物
JP2013504588A (ja) 免疫原性の高いタンパク質マトリックスワクチン
Khatun et al. Immunogenicity assessment of cell wall carbohydrates of Group A Streptococcus via self-adjuvanted glyco-lipopeptides
WO2023202607A1 (zh) 多价肺炎球菌多糖结合疫苗的成分及其应用
US12397014B2 (en) Polysaccharide compositions for use in treating filariasis
Wang et al. Immunological studies of Burkholderia multivorans O-antigen oligosaccharide-rsScpA193 conjugates as potential candidates for vaccine development
US20250186596A1 (en) A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
HK1220360B (en) Conjugate for inducing antibodies targeting fungal cell wall polysaccharides
US20250186595A1 (en) A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
RU2818894C1 (ru) Свободные от примеси с-полисахарида капсульные полисахариды streptococcus pneumoniae с остатком 2,5-ангидроманнозы на восстанавливающем конце
AT525943B1 (de) Konjugat bestehend aus oder umfassend zumindest ein β-Glucan oder ein Mannan
JP2021502957A (ja) ワクチン
Priegue Piñeiro Development and Evaluation of Glycan-based Strategies Against Pathogenic Gram-negative Bacteria
Piñeiro Development and Evaluation of Glycan-based Strategies Against Pathogenic Gram-negative Bacteria
Alcazar-Fuoli et al. Ema Pauloviˇcová 1*, Lucia Pauloviˇcová 1, Pavol Farkaš 1, Alexander Yury E. Tsvetkov 2, Vadim B. Krylov2 and Nikolay E. Nifantiev2* A. Karelin 2